JP2014522855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522855A5 JP2014522855A5 JP2014519688A JP2014519688A JP2014522855A5 JP 2014522855 A5 JP2014522855 A5 JP 2014522855A5 JP 2014519688 A JP2014519688 A JP 2014519688A JP 2014519688 A JP2014519688 A JP 2014519688A JP 2014522855 A5 JP2014522855 A5 JP 2014522855A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidin
- oxo
- benzoyl
- pyrrolidin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims 5
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical class C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 claims 4
- -1 3- (4- (4-methoxybenzoyl) piperidin-1-yl) -2-oxopyrrolidin-1-yl Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical group CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
- FMURKSCWRQGCFO-OAQYLSRUSA-N 2-[[(3r)-3-(6-methoxy-3-oxospiro[1h-indene-2,4'-piperidine]-1'-yl)-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1OCCC(N2)=C1C(=O)N=C2CN(C1=O)CC[C@H]1N(CC1)CCC11C(=O)C2=CC=C(OC)C=C2C1 FMURKSCWRQGCFO-OAQYLSRUSA-N 0.000 claims 1
- DDIZJESACWEABB-HXUWFJFHSA-N 2-[[(3r)-3-[4-(4-fluorobenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN([C@H]2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 DDIZJESACWEABB-HXUWFJFHSA-N 0.000 claims 1
- BVCFVQGPDDYTEY-OAQYLSRUSA-N 2-[[(3r)-3-[4-(4-methoxy-3-methylbenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=C(C)C(OC)=CC=C1C(=O)C1CCN([C@H]2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 BVCFVQGPDDYTEY-OAQYLSRUSA-N 0.000 claims 1
- DUCZLEBAUSAZOC-OAQYLSRUSA-N 2-[[(3r)-3-[4-(4-methoxy-3-methylbenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1h-cyclohepta[d]imidazol-4-one Chemical compound C1=C(C)C(OC)=CC=C1C(=O)C1CCN([C@H]2C(N(CC=3NC4=C(C(C=CC=C4)=O)N=3)CC2)=O)CC1 DUCZLEBAUSAZOC-OAQYLSRUSA-N 0.000 claims 1
- QWYIBGOLIBASGM-OAQYLSRUSA-N 2-[[(3r)-3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN([C@H]2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 QWYIBGOLIBASGM-OAQYLSRUSA-N 0.000 claims 1
- FMURKSCWRQGCFO-NRFANRHFSA-N 2-[[(3s)-3-(6-methoxy-3-oxospiro[1h-indene-2,4'-piperidine]-1'-yl)-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1OCCC(N2)=C1C(=O)N=C2CN(C1=O)CC[C@@H]1N(CC1)CCC11C(=O)C2=CC=C(OC)C=C2C1 FMURKSCWRQGCFO-NRFANRHFSA-N 0.000 claims 1
- DDIZJESACWEABB-FQEVSTJZSA-N 2-[[(3s)-3-[4-(4-fluorobenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN([C@@H]2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 DDIZJESACWEABB-FQEVSTJZSA-N 0.000 claims 1
- FMURKSCWRQGCFO-UHFFFAOYSA-N 2-[[3-(6-methoxy-3-oxospiro[1h-indene-2,4'-piperidine]-1'-yl)-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1OCCC(N2)=C1C(=O)N=C2CN(C1=O)CCC1N(CC1)CCC11C(=O)C2=CC=C(OC)C=C2C1 FMURKSCWRQGCFO-UHFFFAOYSA-N 0.000 claims 1
- LJLQEWDFIMKBSL-UHFFFAOYSA-N 2-[[3-[4-(4-chlorobenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 LJLQEWDFIMKBSL-UHFFFAOYSA-N 0.000 claims 1
- DDIZJESACWEABB-UHFFFAOYSA-N 2-[[3-[4-(4-fluorobenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 DDIZJESACWEABB-UHFFFAOYSA-N 0.000 claims 1
- QOUNQNYSBYTMLY-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopiperidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CCC2)=O)CC1 QOUNQNYSBYTMLY-UHFFFAOYSA-N 0.000 claims 1
- QWYIBGOLIBASGM-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC=4CCOCC=4C(=O)N=3)CC2)=O)CC1 QWYIBGOLIBASGM-UHFFFAOYSA-N 0.000 claims 1
- ZGPMZIHTBVGHFX-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1h-pyrimidin-6-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(=O)C=CN=3)CC2)=O)CC1 ZGPMZIHTBVGHFX-UHFFFAOYSA-N 0.000 claims 1
- ZOLNILZRLCDHDN-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-4a,7a-dihydro-3h-thieno[3,2-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(=O)C4SC=CC4N=3)CC2)=O)CC1 ZOLNILZRLCDHDN-UHFFFAOYSA-N 0.000 claims 1
- HTWNXILBIKZTTF-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-5,6-dimethyl-1h-pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(C)=C(C)C(=O)N=3)CC2)=O)CC1 HTWNXILBIKZTTF-UHFFFAOYSA-N 0.000 claims 1
- VNXUSDDWRYWPQI-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-5-methyl-1h-pyrimidin-6-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(=O)C(C)=CN=3)CC2)=O)CC1 VNXUSDDWRYWPQI-UHFFFAOYSA-N 0.000 claims 1
- TVSSLHKEVCLVAI-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-6-methyl-1h-pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(C)=CC(=O)N=3)CC2)=O)CC1 TVSSLHKEVCLVAI-UHFFFAOYSA-N 0.000 claims 1
- DVIHZULFCIMZGZ-UHFFFAOYSA-N 2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-6-methyl-4a,7a-dihydro-3h-thieno[2,3-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(=O)C4C=C(C)SC4N=3)CC2)=O)CC1 DVIHZULFCIMZGZ-UHFFFAOYSA-N 0.000 claims 1
- PERWUJINIMBCAY-UHFFFAOYSA-N 2-chloro-5-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3C=C(C(Cl)=CC=3)C#N)CC2)=O)CC1 PERWUJINIMBCAY-UHFFFAOYSA-N 0.000 claims 1
- OXTYNMCLCNPCJW-UHFFFAOYSA-N 2-chloro-6-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3C(=C(Cl)C=CC=3)C#N)CC2)=O)CC1 OXTYNMCLCNPCJW-UHFFFAOYSA-N 0.000 claims 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- BHLYXUCYNUOODH-UHFFFAOYSA-N 6-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1-methyl-5,7a-dihydro-3ah-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC=3NC(=O)C4C(N(N=C4)C)N=3)CC2)=O)CC1 BHLYXUCYNUOODH-UHFFFAOYSA-N 0.000 claims 1
- DEGIMKQHUITSSN-UHFFFAOYSA-N 6-ethyl-2-[[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]methyl]-1h-pyrimidin-4-one Chemical compound N1C(CC)=CC(=O)N=C1CN1C(=O)C(N2CCC(CC2)C(=O)C=2C=CC(OC)=CC=2)CC1 DEGIMKQHUITSSN-UHFFFAOYSA-N 0.000 claims 1
- LWZRQSRLJJMSHR-UHFFFAOYSA-N COC1=CC=C(C=C1)C(=O)C2CCN(CC2)C3CCN(C3=O)CC4CC5CCCCC(=O)C5N4 Chemical compound COC1=CC=C(C=C1)C(=O)C2CCN(CC2)C3CCN(C3=O)CC4CC5CCCCC(=O)C5N4 LWZRQSRLJJMSHR-UHFFFAOYSA-N 0.000 claims 1
- LWZRQSRLJJMSHR-HCSIYLKJSA-N COC1=CC=C(C=C1)C(=O)C2CCN(CC2)[C@@H]3CCN(C3=O)CC4CC5CCCCC(=O)C5N4 Chemical compound COC1=CC=C(C=C1)C(=O)C2CCN(CC2)[C@@H]3CCN(C3=O)CC4CC5CCCCC(=O)C5N4 LWZRQSRLJJMSHR-HCSIYLKJSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- JDZOLLKCZDHXOE-UHFFFAOYSA-N n-(3,4-dihydro-2h-pyrano[2,3-d]pyridazin-5-yl)-2-[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC(=O)NC=3C=4CCCOC=4C=NN=3)CC2)=O)CC1 JDZOLLKCZDHXOE-UHFFFAOYSA-N 0.000 claims 1
- PADREXIRIZBNMQ-GOSISDBHSA-N n-(5,6-dihydro-[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl)-2-[(3r)-3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN([C@H]2C(N(CC(=O)NC=3N4CCSC4=NN=3)CC2)=O)CC1 PADREXIRIZBNMQ-GOSISDBHSA-N 0.000 claims 1
- PADREXIRIZBNMQ-SFHVURJKSA-N n-(5,6-dihydro-[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl)-2-[(3s)-3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN([C@@H]2C(N(CC(=O)NC=3N4CCSC4=NN=3)CC2)=O)CC1 PADREXIRIZBNMQ-SFHVURJKSA-N 0.000 claims 1
- PADREXIRIZBNMQ-UHFFFAOYSA-N n-(5,6-dihydro-[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl)-2-[3-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-oxopyrrolidin-1-yl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C2C(N(CC(=O)NC=3N4CCSC4=NN=3)CC2)=O)CC1 PADREXIRIZBNMQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- YUBFIWOTPFWWDX-UHFFFAOYSA-N pyrano[4,3-d]pyrimidin-4-one Chemical compound C1=COC=C2C(=O)N=CN=C21 YUBFIWOTPFWWDX-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507321P | 2011-07-13 | 2011-07-13 | |
| US61/507,321 | 2011-07-13 | ||
| PCT/IB2012/053613 WO2013008217A1 (en) | 2011-07-13 | 2012-07-13 | 4 - piperidinyl compounds for use as tankyrase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522855A JP2014522855A (ja) | 2014-09-08 |
| JP2014522855A5 true JP2014522855A5 (enExample) | 2015-08-06 |
| JP5957077B2 JP5957077B2 (ja) | 2016-07-27 |
Family
ID=46604017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519688A Expired - Fee Related JP5957077B2 (ja) | 2011-07-13 | 2012-07-13 | タンキラーゼ阻害剤として使用するための４−ピペリジニル化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | USRE46942E1 (enExample) |
| EP (1) | EP2731940B1 (enExample) |
| JP (1) | JP5957077B2 (enExample) |
| KR (1) | KR20140051944A (enExample) |
| CN (1) | CN103797006B (enExample) |
| AP (1) | AP2014007400A0 (enExample) |
| AU (1) | AU2012282076A1 (enExample) |
| BR (1) | BR112014000792A2 (enExample) |
| CA (1) | CA2841932A1 (enExample) |
| CO (1) | CO6880065A2 (enExample) |
| CR (1) | CR20140071A (enExample) |
| DO (1) | DOP2014000012A (enExample) |
| EA (1) | EA201490272A1 (enExample) |
| ES (1) | ES2548513T3 (enExample) |
| IL (1) | IL230430A0 (enExample) |
| MA (1) | MA35342B1 (enExample) |
| MX (1) | MX2014000536A (enExample) |
| PH (1) | PH12014500126A1 (enExample) |
| TN (1) | TN2014000016A1 (enExample) |
| WO (1) | WO2013008217A1 (enExample) |
| ZA (1) | ZA201400374B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014520858A (ja) * | 2011-07-13 | 2014-08-25 | ノバルティス アーゲー | タンキラーゼ阻害剤として用いるための新規な２−ピペリジン−１−イル−アセトアミド化合物 |
| DK2822656T3 (en) | 2012-03-07 | 2017-01-30 | Inst Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| TW201524952A (zh) * | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| WO2015018475A1 (en) | 2013-08-07 | 2015-02-12 | Merck Patent Gmbh | Piperidine urea derivatives |
| CN105722835B (zh) | 2013-09-11 | 2018-07-31 | 癌症研究协会:皇家癌症医院 | 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用 |
| CN105793264B (zh) * | 2014-03-10 | 2017-09-01 | 四川海思科制药有限公司 | 取代的二氢苯并呋喃‑哌啶‑甲酮衍生物、其制备及用途 |
| AU2015258100B2 (en) | 2014-05-07 | 2019-05-16 | Merck Patent Gmbh | Heterocyclyl-butanamide derivatives |
| WO2016006974A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
| KR101739003B1 (ko) | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| RU2018119935A (ru) * | 2015-11-02 | 2019-12-04 | Мерк Патент Гмбх | 1,4-дикарбонилпиперидильные производные |
| KR101777475B1 (ko) | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| EP3891136B1 (en) | 2018-12-03 | 2023-07-19 | Merck Patent GmbH | 4-heteroarylcarbonyl-n-(phenyl or heteroaryl)piperidine-1-carboxamides as inhibitors of tankyrases |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| US12435046B2 (en) | 2019-08-15 | 2025-10-07 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| WO2022146614A1 (en) * | 2020-12-03 | 2022-07-07 | Washington University | Methods of treating and preventing kidney disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| AU2004200A (en) | 1999-01-14 | 2000-08-01 | Meiji Seika Kaisha Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DE10056312A1 (de) | 2000-11-14 | 2002-05-16 | Bayer Ag | Substituierte Amidoalkyluracile und ihre Verwendung |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| EP1551812B1 (en) | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| DE10201240A1 (de) | 2002-01-15 | 2003-07-24 | Bayer Ag | Substituierte Alkyluracile und ihre Verwendung |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| EP1477175B1 (en) | 2002-02-19 | 2011-04-27 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| US7439254B2 (en) | 2003-12-08 | 2008-10-21 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| EA012837B1 (ru) * | 2004-06-30 | 2009-12-30 | Янссен Фармацевтика Н.В. | Производные хиназолинона в качестве ингибиторов parp |
| KR20150002863A (ko) | 2004-09-02 | 2015-01-07 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2007016270A (es) | 2005-06-27 | 2008-03-05 | Amgen Inc | Compuestos aril nitrilo anti-inflamatorios. |
| ES2336849T3 (es) * | 2006-04-25 | 2010-04-16 | Eli Lilly And Company | Inhibidores de 11-beta-hidroxiesteroide dehidrogenasa 1. |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| BRPI0820504A2 (pt) | 2007-11-05 | 2015-06-16 | Novartis Ag | Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt |
| KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2271626B1 (en) | 2008-03-27 | 2014-11-26 | Janssen Pharmaceutica, N.V. | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
| JP2014520858A (ja) * | 2011-07-13 | 2014-08-25 | ノバルティス アーゲー | タンキラーゼ阻害剤として用いるための新規な２−ピペリジン−１−イル−アセトアミド化合物 |
-
2012
- 2012-07-13 PH PH1/2014/500126A patent/PH12014500126A1/en unknown
- 2012-07-13 BR BR112014000792A patent/BR112014000792A2/pt not_active IP Right Cessation
- 2012-07-13 CA CA 2841932 patent/CA2841932A1/en not_active Abandoned
- 2012-07-13 CN CN201280043558.7A patent/CN103797006B/zh not_active Expired - Fee Related
- 2012-07-13 JP JP2014519688A patent/JP5957077B2/ja not_active Expired - Fee Related
- 2012-07-13 AU AU2012282076A patent/AU2012282076A1/en not_active Abandoned
- 2012-07-13 EP EP12742957.9A patent/EP2731940B1/en not_active Not-in-force
- 2012-07-13 AP AP2014007400A patent/AP2014007400A0/xx unknown
- 2012-07-13 KR KR20147003628A patent/KR20140051944A/ko not_active Withdrawn
- 2012-07-13 US US15/786,125 patent/USRE46942E1/en active Active
- 2012-07-13 EA EA201490272A patent/EA201490272A1/ru unknown
- 2012-07-13 MX MX2014000536A patent/MX2014000536A/es not_active Application Discontinuation
- 2012-07-13 US US14/154,173 patent/US9163003B2/en not_active Ceased
- 2012-07-13 ES ES12742957.9T patent/ES2548513T3/es active Active
- 2012-07-13 WO PCT/IB2012/053613 patent/WO2013008217A1/en not_active Ceased
-
2014
- 2014-01-13 IL IL230430A patent/IL230430A0/en unknown
- 2014-01-15 TN TNP2014000016A patent/TN2014000016A1/en unknown
- 2014-01-17 ZA ZA2014/00374A patent/ZA201400374B/en unknown
- 2014-01-22 DO DO2014000012A patent/DOP2014000012A/es unknown
- 2014-02-10 MA MA36745A patent/MA35342B1/fr unknown
- 2014-02-12 CR CR20140071A patent/CR20140071A/es unknown
- 2014-02-13 CO CO14031176A patent/CO6880065A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014522855A5 (enExample) | ||
| ES2561277T3 (es) | Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas | |
| CN112166110B (zh) | Shp2磷酸酶抑制剂及其使用方法 | |
| US9556197B2 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| JP7654071B2 (ja) | 複素環スピロ化合物及び使用方法 | |
| JP2015500332A5 (enExample) | ||
| AU2022210517A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| HRP20230086T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| US20200172546A1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| JP2018500376A5 (enExample) | ||
| JP2016531874A5 (enExample) | ||
| RU2009125024A (ru) | Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов | |
| JP2016528298A5 (enExample) | ||
| HRP20190947T1 (hr) | Heterociklički spoj | |
| JP2015522002A5 (enExample) | ||
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| HRP20171150T1 (hr) | Novi spojevi | |
| JP2015511245A5 (enExample) | ||
| JP2009507758A5 (enExample) | ||
| HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
| JP2017510576A5 (enExample) | ||
| JP2011522866A5 (enExample) | ||
| HRP20170484T1 (hr) | Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze | |
| JP2013515729A5 (enExample) |